Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 815.8 INR -1.94% Market Closed
Market Cap: ₹146.1B

Operating Margin

33.8%
Current
Declining
by 3.2%
vs 3-y average of 37%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
33.8%
=
Operating Income
₹14.8B
/
Revenue
₹43.9B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
33.8%
=
Operating Income
₹14.8B
/
Revenue
₹43.9B

Peer Comparison

Country Company Market Cap Operating
Margin
IN
Natco Pharma Ltd
NSE:NATCOPHARM
146B INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
223.2B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.1B EUR
Loading...

Market Distribution

Higher than 91% of companies in India
Percentile
91th
Based on 5 437 companies
91th percentile
33.8%
Low
-153 833.3% — 2.7%
Typical Range
2.7% — 13.2%
High
13.2% — 9 977%
Distribution Statistics
India
Min -153 833.3%
30th Percentile 2.7%
Median 7.3%
70th Percentile 13.2%
Max 9 977%

Natco Pharma Ltd
Glance View

Nestled in the bustling business corridors of Hyderabad, India, Natco Pharma Ltd. has cultivated a strong presence in the pharmaceutical industry over the decades. Founded in 1981, the company initially ventured into the local market, gradually establishing itself as a critical player through specialization in complex chemistry and niche therapeutic sectors. The company's primary focus is on the development and manufacturing of generic drugs, specifically in the oncology and neurology segments. In these high-stakes areas, Natco leverages its robust research and development capabilities to produce affordable alternatives to expensive branded medications, thereby ensuring access to critical treatments for broader populations. Natco Pharma's business acumen extends beyond merely producing generics. It is adept at capitalizing on patent expirations, quickly launching generics and biosimilars in both domestic and international markets. The company has strategically focused operations in markets such as the United States and Europe, where it partners with local distributors to reach end-users. Through a combination of manufacturing efficiencies and strategic partnerships, Natco is able to maintain competitive pricing, thus enhancing its market penetration and revenue generation. Its integrated business model, combining in-house R&D, manufacturing, and distribution, ensures that Natco remains a formidable player, bridging the gap between complex pharmaceuticals and cost-effective healthcare solutions.

NATCOPHARM Intrinsic Value
803.84 INR
Overvaluation 1%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
33.8%
=
Operating Income
₹14.8B
/
Revenue
₹43.9B
What is Natco Pharma Ltd's current Operating Margin?

The current Operating Margin for Natco Pharma Ltd is 33.8%, which is below its 3-year median of 37%.

How has Operating Margin changed over time?

Over the last 3 years, Natco Pharma Ltd’s Operating Margin has increased from 16.9% to 33.8%. During this period, it reached a low of 16.9% on Sep 30, 2022 and a high of 47.9% on Sep 30, 2024.

Back to Top